Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    Heavy Birth Weight Doubles Risk of Developing Rheumatoid Arthritis - (DGNews)
    EMEA Recommends Updated Label Warnings for Etoricoxib-Containing Drugs - (DGNews)
    TopAbstracts in Rheumatoid Arthritis 06/26/2008 - (DGNews)
    Etanercept Plus Methotrexate Prevents Joint Damage in Early Active Rheumatoid Arthritis: Presented at EULAR - (DGDispatch)
    Abatacept and Infliximab Improve ACR and LDAS in Methotrexate-Refractory RA Patients - (DGNews)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
    • Beyond Efficacy and Safety in Rheumatoid Arthritis Treatment: Quality-of-Life Outcomes With Newer Biologics in RA
    • Long-Term Data on Abatacept and Rituximab Show Continued Efficacy in Rheumatoid Arthritis
    • Are Rituximab and Abatacept Safe Over the Long Term in Rheumatoid Arthritis?
    • Pathology and Treatment of Rheumatoid Arthritis: The Role of IL-6 in Inflammation and Rheumatoid Arthritis
      Systemic Pathology of Rheumatoid Arthritis

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Rheumatoid Nodule of the Thyrohyoid Membrane: A Case Report
        Recurrent Pneumothorax in a Patient with Rheumatoid Arthritis on Leflunomide Treatment: Case Report and Overview of the Literature
        Spontaneous Esophageal Perforation in a Patient with Achalasia Cardia and Rheumatoid Arthritis
        Rheumatoid Arthritis in Thalassemia Intermedia: Coincidence or Association?
        Gamma/Delta T-cell Receptor Type Granular Lymphocyte Proliferative Disorder Associated with Rheumatoid Arthritis

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Leflunomide Dose Should Not Be Reduced in Active Rheumatoid Arthritis: Presented at EULAR

        By Adrian Burton

        LISBON, PORTUGAL -- June 20, 2003 -- The standard dose of 20 mg/day of leflunomide cannot be reduced if full efficacy is to be maintained in patients with active rheumatoid arthritis– and reducing the dose does not reduce the risk of side effects, researchers reported here June 19th at the Annual European Congress of Rheumatology.

        "The usual dose is 20 mg/day," explained Gyula Poor, a professor of rheumatology at the National Institute of Rheumatology and Physiotherapy, in Budapest, Hungary. "But we were interested in whether we could reduce the dose to 10 mg/day to see if this was not inferior, and to see if we could reduce side effects."

        In a phase IIIb, 12-country trial, Dr. Poor and colleagues randomised 202 subjects to receive leflunomide 10 mg/day and 200 to receive 20 mg/day of leflunomide following a 100 mg loading dose. Baseline demographic and disease characteristics of the two groups were not significantly different.

        The efficacy of the two doses was evaluated by tender and swollen joint counts, and the Health Assessment Questionnaire Disability Index (HAQDI).

        At the 16-week end point, the mean reduction in the number of tender joints for the 10 mg and 20 mg groups was 7.57 and 8.89, respectively (P=0.0617). With respect to mean HAQDI score, the 10 mg group saw a reduction of 0.37 and the 20 mg group a reduction of 0.49 (P=0.0946).

        Although there was no significant difference in the reduction of the mean number of swollen joints between the two groups (-6.38 for the 10 mg group and –6.96 in the 20 mg group), overall, the results clearly show the 10 mg regimen to be inferior, Dr. Poor said.

        The inferior efficacy of the 10 mg regimen was not compensated for by lower incidence of side effects, the research shows. No significant differences were seen in the number of patients in both groups show developed diarrhoea, alopecia, nausea, hypertension, headache and gastrointestinal pain.

        "The message to take home is please stick to the 20 mg regimen," concluded Dr. Poor.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send